Abstract | BACKGROUND: METHODS: RESULTS: The annual percentage increase in total kidney volume was significantly lower in the low-blood-pressure group than in the standard-blood-pressure group (5.6% vs. 6.6%, P=0.006), without significant differences between the lisinopril- telmisartan group and the lisinopril-placebo group. The rate of change in estimated GFR was similar in the two medication groups, with a negative slope difference in the short term in the low-blood-pressure group as compared with the standard-blood-pressure group (P<0.001) and a marginally positive slope difference in the long term (P=0.05). The left-ventricular-mass index decreased more in the low-blood-pressure group than in the standard-blood-pressure group (-1.17 vs. -0.57 g per square meter per year, P<0.001); urinary albumin excretion was reduced by 3.77% with the low-pressure target and increased by 2.43% with the standard target (P<0.001). Dizziness and light-headedness were more common in the low-blood-pressure group than in the standard-blood-pressure group (80.7% vs. 69.4%, P=0.002). CONCLUSIONS: In early ADPKD, the combination of lisinopril and telmisartan did not significantly alter the rate of increase in total kidney volume. As compared with standard blood-pressure control, rigorous blood-pressure control was associated with a slower increase in total kidney volume, no overall change in the estimated GFR, a greater decline in the left-ventricular-mass index, and greater reduction in urinary albumin excretion. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; HALT-PKD [Study A] ClinicalTrials.gov number, NCT00283686.).
|
Authors | Robert W Schrier, Kaleab Z Abebe, Ronald D Perrone, Vicente E Torres, William E Braun, Theodore I Steinman, Franz T Winklhofer, Godela Brosnahan, Peter G Czarnecki, Marie C Hogan, Dana C Miskulin, Frederic F Rahbari-Oskoui, Jared J Grantham, Peter C Harris, Michael F Flessner, Kyongtae T Bae, Charity G Moore, Arlene B Chapman, HALT-PKD Trial Investigators |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 371
Issue 24
Pg. 2255-66
(Dec 11 2014)
ISSN: 1533-4406 [Electronic] United States |
PMID | 25399733
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Benzimidazoles
- Benzoates
- Lisinopril
- Telmisartan
|
Topics |
- Adolescent
- Adult
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Antihypertensive Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Benzoates
(therapeutic use)
- Blood Pressure
(drug effects)
- Disease Progression
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Glomerular Filtration Rate
- Humans
- Hypertension
(drug therapy, etiology)
- Kidney
(pathology)
- Lisinopril
(therapeutic use)
- Male
- Middle Aged
- Organ Size
(drug effects)
- Polycystic Kidney, Autosomal Dominant
(drug therapy, pathology, physiopathology)
- Telmisartan
- Young Adult
|